{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:45:39Z","timestamp":1792183539880,"version":"4.4.0"},"reference-count":88,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with advanced thyroid (TC) or biliary tract cancer (BTC) with\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      V600E mutations treated with cobimetinib plus vemurafenib (C + V) are reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients had measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; \u03b1 = .10). Both cohorts expanded to stage II but closed before reaching the target sample size by pharmaceutical company request; inferences are based on thresholds set forth in the protocol to maintain the \u03b1 level. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of SD, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with TC (N = 22; n = 16 evaluable) or BTC (N = 18; n = 15 evaluable) with\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      V600E mutations were enrolled. In the TC cohort, the DC and OR rates were 94% (one-sided 90% CI, 78 to 100) and 63% (95% CI, 35 to 85), respectively. In the BTC cohort, the DC and OR rates were 67% (one-sided 90% CI, 47 to 100) and 53% (95% CI, 27 to 79), respectively. The null hypothesis of 15% DC rate was rejected for both cohorts (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001). Twenty-one patients (53%) had \u22651 treatment-related grade 3 to 4 adverse event (AE) or serious AE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The combination of C + V met the prespecified criteria to declare a signal of activity in patients with TC and BTC with\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      V600E mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00703","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:59:09Z","timestamp":1792180749000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Cobimetinib + Vemurafenib in Patients With\n                    <i>BRAF<\/i>\n                    V600E\u2013Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study"],"prefix":"10.1200","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2327-0513","authenticated-orcid":true,"given":"Samantha A.","family":"Diamond-Rossi","sequence":"first","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-7285","authenticated-orcid":true,"given":"Jonathan","family":"Bleeker","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-2671","authenticated-orcid":true,"given":"Apar Kishor","family":"Ganti","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center and VA NWIHCS, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-1652","authenticated-orcid":true,"given":"Justin T.","family":"Moyers","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-9732","authenticated-orcid":true,"given":"Suresh G.","family":"Nair","sequence":"additional","affiliation":[{"name":"Michigan Cancer Research Consortium, Lehigh Valley Topper Cancer Institute, Allentown, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-4141","authenticated-orcid":true,"given":"Kunal C.","family":"Kadakia","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Rohatgi","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":true,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-4759","authenticated-orcid":true,"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Gold","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9769-0850","authenticated-orcid":true,"given":"Manish R.","family":"Sharma","sequence":"additional","affiliation":[{"name":"The Cancer &amp; Hematology Centers and Cancer Research Consortium of West Michigan NCORP, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1498"},{"key":"e_1_3_10_3_2","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose MS","year":"2006","unstructured":"Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2006","journal-title":"Cancer Res"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114440"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220959657"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02541"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00160"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3377"},{"key":"e_1_3_10_9_2","article-title":"Clinical activity of mitogen-activated protein kinase\u2013targeted therapies in patients with Non\u2013V600 BRAF-mutant tumors","author":"Dankner M","unstructured":"Dankner M, Wang Y, Fazelzad R, et al: Clinical activity of mitogen-activated protein kinase\u2013targeted therapies in patients with Non\u2013V600 BRAF-mutant tumors. JCO Precis Oncol 10.1200\/PO.22.00107","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_10_2","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study","author":"Meric-Bernstam F","unstructured":"Meric-Bernstam F, Rothe M, Mangat PK, et al: Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00385","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_11_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00489"},{"key":"e_1_3_10_13_2","article-title":"Non-V600E\/K BRAF mutations in metastatic melanoma: Molecular description, frequency, and effectiveness of targeted therapy in a large national cohort","author":"Girod M","unstructured":"Girod M, Dalle S, Mortier L, et al: Non-V600E\/K BRAF mutations in metastatic melanoma: Molecular description, frequency, and effectiveness of targeted therapy in a large national cohort. JCO Precis Oncol 10.1200\/PO.22.00075","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_14_2","article-title":"Retrospective case series analysis of RAF family alterations in pancreatic cancer: Real-world outcomes from targeted and standard therapies","author":"Hendifar A","unstructured":"Hendifar A, Blais EM, Wolpin B, et al: Retrospective case series analysis of RAF family alterations in pancreatic cancer: Real-world outcomes from targeted and standard therapies. JCO Precis Oncol 10.1200\/PO.20.00494","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29825"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010021"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006023"},{"key":"e_1_3_10_18_2","first-page":"528","article-title":"A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma","volume":"179","author":"Marchand A","year":"2018","unstructured":"Marchand A, Tallet A, Collin C, et al: A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma. Br J Dermatol 179:528-529, 2018","journal-title":"Br J Dermatol"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3585"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68076-7"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3190"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.0978"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318148563d"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603764"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-14935-4"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767"},{"key":"e_1_3_10_27_2","first-page":"631","article-title":"Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification","volume":"19","author":"Gan X","year":"2019","unstructured":"Gan X, Shen F, Deng X, et al: Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification. Oncol Lett 19:631-640, 2019","journal-title":"Oncol Lett"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0399"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.2217\/ije-2017-0016"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04437-z"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30166-8"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"e_1_3_10_33_2","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara M","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H, et al: A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34:467-476, 2024","journal-title":"Thyroid"},{"key":"e_1_3_10_34_2","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy NL","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, et al: Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid 32:1184-1192, 2022","journal-title":"Thyroid"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102447"},{"key":"e_1_3_10_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1265"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00762"},{"key":"e_1_3_10_40_2","article-title":"Rationale and design of the targeted agent and profiling utilization registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_10_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_10_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_10_44_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_45_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702"},{"key":"e_1_3_10_47_2","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, et al: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.19.00124","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_48_2","article-title":"Palbociclib in patients with non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_49_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_50_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_51_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_52_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_10_54_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104545"},{"key":"e_1_3_10_56_2","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry Study","author":"Schuetze S","unstructured":"Schuetze S, Rothe M, Mangat PK, et al: Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.24.00219","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_57_2","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00609","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_58_2","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study","author":"Ganti AK","unstructured":"Ganti AK, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00041","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_59_2","article-title":"Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00649","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_60_2","article-title":"Olaparib in patients with solid tumors with ATM alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Carrizosa DR","unstructured":"Carrizosa DR, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with ATM alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00716","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_61_2","article-title":"Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Worden FP","unstructured":"Worden FP, Pisick E, Rothe M, et al: Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO-24-00477","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_10_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_10_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"e_1_3_10_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"e_1_3_10_66_2","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.215"},{"key":"e_1_3_10_67_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1789"},{"key":"e_1_3_10_68_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00612"},{"key":"e_1_3_10_69_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0143"},{"key":"e_1_3_10_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915"},{"key":"e_1_3_10_71_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01478"},{"key":"e_1_3_10_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03388-6"},{"key":"e_1_3_10_73_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193268"},{"key":"e_1_3_10_74_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.920957"},{"key":"e_1_3_10_75_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092315"},{"key":"e_1_3_10_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.022"},{"key":"e_1_3_10_77_2","article-title":"Real-world genomic characteristics and prognostic association in advanced papillary thyroid carcinoma","author":"Toda S","unstructured":"Toda S, Hiroshima Y, Iwasaki H, et al: Real-world genomic characteristics and prognostic association in advanced papillary thyroid carcinoma. JCO Precis Oncol 10.1200\/PO-25-00520","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02181-8"},{"key":"e_1_3_10_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6008"},{"key":"e_1_3_10_80_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0210"},{"key":"e_1_3_10_81_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3932"},{"key":"e_1_3_10_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3288"},{"key":"e_1_3_10_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5094"},{"key":"e_1_3_10_84_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004707117"},{"key":"e_1_3_10_85_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1694805"},{"key":"e_1_3_10_86_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_10_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70301-8"},{"key":"e_1_3_10_88_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010141"},{"key":"e_1_3_10_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9528"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:59:13Z","timestamp":1792180753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1200\/PO-26-00703"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00703","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600703"}}